Search | Clinical Trials Finder

Conditions: mCRPC
Interventions: Placebo, Senaparib; Drug
Lead sponsor: Impact Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Binghamton, New York

Conditions: Pain
Interventions: Preservative Free Lidocaine, Saline; Drug
Lead sponsor: Antonios Likourezos; Other
Eligibility: 7 Years to 17 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Mood Disorders, Anxiety Disorders, Psychotic Disorders
Interventions: Personalised medication advice based on pharmacogenetic testing; Other
Lead sponsor: Parnassia Groep; Other
Eligibility: 16 Years to 70 Years
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Hypertrophic Cardiomyopathy
Interventions: Echo and myocardial contrast echocardiography perfusion imaging; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 19 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Asthma
Interventions: PL-3994; Drug
Lead sponsor: Palatin Technologies, Inc; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Cranbury, New Jersey

Conditions: Disaster, Vulnerable Populations
Interventions: Nurses Taking On Readiness Measures (N-TORM); Behavioral
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 44
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more

Conditions: Miscarriage, Recurrent, Abortion, Habitual
Interventions: Gamimune N or Gamunex 10%, normal saline; Biological · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Painful Peripheral Neuropathy, Diabetic Peripheral Neuropathic Pain (DPN), Chemotherapy Induced Peripheral Neuropathy (CIPN), Idiopathic Peripheral Neuropathy
Interventions: Pregabalin, Duloxetine, Placebo; Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 80 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Boston, Massachusetts • New York, New York • Rochester, New York + 4 more

Conditions: Urticaria
Interventions: Omalizumab, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 40
States / cities: Granada Hills, California • Long Beach, California • Los Angeles, California + 36 more

Conditions: Moderate Gastrointestinal Discomfort
Interventions: BIOHM FX Probiotic Blend; Dietary Supplement
Lead sponsor: Biohm Technologies; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Delirium, Lumbar Radiculopathy, Lumbar Osteoarthritis, Lumbar Spine Disc Degeneration
Interventions: Light sedation with propofol, Induction with propofol, Maintenance anesthetic using a volatile anesthetic, Muscle relaxant during maintenance anesthesia, Pain control with fentanyl, Bispectral Index (BIS) monitoring for depth of anesthesia, Spinal Anesthesia, Midazolam administered during spinal anesthesia, Cerebrospinal fluid collection, Administration of intrathecal morphine; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple Sclerosis
Interventions: IMU-838 tablets, Placebo matching IMU-838 tablets; Drug
Lead sponsor: Immunic AG; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 1,121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2033
U.S. locations: 6
States / cities: Phoenix, Arizona • West Hollywood, California • Bradenton, Florida + 3 more

Conditions: Chronic Low Back Pain
Interventions: Naproxen, Omeprazole, Placebo; Drug
Lead sponsor: Apkar Apkarian; Other
Eligibility: 18 Years to 75 Years
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Advanced Solid Tumors
Interventions: palifosfamide-tris, Normal Saline; Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: Dallas, Texas • Houston, Texas • San Antonio, Texas

Conditions: Tobacco Use Disorder
Interventions: Cue Extinction Training, Nicotine Replacement Therapy, Cue Extinction Therapy, Progressive Muscle Relaxation; Behavioral · Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Rotator Cuff Tear Surgical Repair
Interventions: Routine post-surgical care plus H-Wave® Device Stimulation (HWDS), Routine post-surgical care; Device · Other
Lead sponsor: Electronic Waveform Lab; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Overland Park, Kansas • Kansas City, Missouri • Lee's Summit, Missouri + 1 more

Conditions: Fatigue
Interventions: DGB-01 Supplementation; Dietary Supplement
Lead sponsor: William Black; Other
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions: Bazedoxifene Acetate; Drug
Lead sponsor: Riley Bove, MD; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Nasal Vestibulitis
Interventions: Placebo Administration, Questionnaire Administration, Rose Geranium in Sesame Oil Nasal Spray; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Albert Lea, Minnesota • Brainerd, Minnesota • Deer River, Minnesota + 16 more

Conditions: Pain, Obstetric
Interventions: Bupivacaine Liposome Injectable Product, 0.25% plain bupivacaine; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Oral Lenacapavir (LEN), F/TDF, Sub-cutaneous (SC) Lenacapavir (LEN), Placebo SC LEN, PTM F/TDF, PTM Oral LEN, F/TAF (for US participants only); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 3,292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 60
States / cities: Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 43 more

Conditions: Osteoarthritis, Knee
Interventions: Dronabinol, Placebo; Drug · Other
Lead sponsor: Colorado Joint Replacement; Other
Eligibility: 21 Years to 75 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Genetic Diseases, Genetic Syndrome, Mendelian Disorders
Interventions: Genomic sequencing and molecular diagnostic results, if any.; Genetic
Lead sponsor: Rady Pediatric Genomics & Systems Medicine Institute; Other
Eligibility: Up to 4 Months
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: San Diego, California

Search by objective public record fields.

Senaparib in mCRPC Patients With Homologous Recombination Repair Gene Alterations After Docetaxel Treatment

The Effect of Pretreatment With Intravenous Lidocaine for Intravenous Contrast:

Clinical Study Evaluating Pharmacogenomics-informed Pharmacotherapy Versus Dosing as Usual in Psychiatric Disorders

Perfusion Imaging With Myocardial Contrast Echocardiography in HCM

Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma

Nurses Taking On Readiness Measures - Mercer County, New Jersey

A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine

Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

SPENDD: Quantitative Sensory Testing and Analgesic Response for Painful Peripheral Neuropathy.

A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria

Investigating the Effectiveness of 2 Different Doses of BIOHM FX Probiotic Blend in Improving Digestive Symptoms

Shaping Anesthetic Techniques to Reduce Post-operative Delirium

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

Placebo In Chronic Back Pain (Phase 2)

Effect on QTc, Pharmacokinetics, Safety, and Preliminary Efficacy of Single-agent Palifosfamide-tris in Subjects With Advanced Solid Tumors

Effects of Nicotine Replacement and Repeated Cue Exposure on Cigarette Craving

H-Wave® Device Stimulation for Post-operative Rotator Cuff Repair Surgery

DGB-01 Effects on Endurance Exercise

Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis

Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy

Efficacy of Extended-Release Liposomal Bupivacaine for Post-Partum Pain Management Following Obstetrical Laceration

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection

A RCT Comparing Dronabinol to a Placebo for Post-operative Pain in Total Joint Arthroplasty

Perinatal Precision Medicine